Market News AIOpen the app

BioLineRx and Hemispherian shared new research at ESMO 2026 showing GLIX1 works well with PARP inhibitors.

TrialRead the original at prnewswire.com
Good for BLRX

BioLineRx reported that GLIX1 combined with PARP inhibitors reduced tumor growth in ovarian cancer models. These were lab and animal results, not results in people, but they support further study of a possible new use.

BLRX · BioLineRx Ltd.

AI read · Good for BLRX

The AI's read

These findings could give GLIX1 a role alongside PARP inhibitors in ovarian cancer. The reported tumor-growth reduction supports that possibility. But the results came from lab and animal models, and further study in people is still needed.

Get alerts for BLRX

Follow BioLineRx Ltd. (BLRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BLRX
Free on the App Store and Google Play, or on the web.